Skip to main content
Explore URMC

IHAN21022 / VX15-2503-12 / KEYNOTE B84 / Baumgart

Research Question:
not to be listed

Basic Study Information

The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Megan Baumgart

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search